2 years ago

Turbine Raises Additional €5.5 Million in Series A Funding

  • Turbine, a London-based biopharma R&D company, secured an additional €5.5 million in Series A funding, bringing the total raised to €25.5 million

  • Led by MassMutual Ventures (MMV), this investment will fuel the advancement of Turbine's internal pipeline of simulation-guided programs and expand its biology simulation platform for partnerships

  • Founded in 2015, Turbine utilizes cell simulations to represent patient populations and perform large-scale assays, validating promising hypotheses through a proprietary closed-loop learning process

  • The company boasts multiple in vivo validated assets in its proprietary and partnered pipeline and operates offices in London, Budapest, and Cambridge.

      • ProblemHealthcare

      "Turbine aims to address the challenge of guiding biopharma research and development (R&D) more effectively, particularly in bringing the right drug to every patient in need."

      Solution

      "Turbine uses advanced cell simulations to guide biopharma R&D, offering the ability to represent patient populations in simulations that are not feasible with traditional biological models. It also performs high-throughput assays in simulations that would be impractical in real-world scenarios."

      Covered on